Kayne Anderson Rudnick Investment Management LLC Sells 134,284 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Kayne Anderson Rudnick Investment Management LLC lessened its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 6.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,805,541 shares of the medical research company's stock after selling 134,284 shares during the period. Kayne Anderson Rudnick Investment Management LLC owned approximately 3.53% of Charles River Laboratories International worth $333,303,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the business. Flagship Harbor Advisors LLC bought a new stake in shares of Charles River Laboratories International in the fourth quarter worth about $237,000. Blue Trust Inc. increased its stake in Charles River Laboratories International by 7.8% in the 4th quarter. Blue Trust Inc. now owns 2,023 shares of the medical research company's stock worth $398,000 after buying an additional 146 shares in the last quarter. KBC Group NV increased its holdings in shares of Charles River Laboratories International by 0.9% in the fourth quarter. KBC Group NV now owns 85,362 shares of the medical research company's stock worth $15,758,000 after purchasing an additional 796 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its holdings in Charles River Laboratories International by 3.0% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 4,354 shares of the medical research company's stock valued at $804,000 after acquiring an additional 126 shares during the period. Finally, Forsta AP Fonden increased its holdings in Charles River Laboratories International by 6.6% during the fourth quarter. Forsta AP Fonden now owns 11,300 shares of the medical research company's stock valued at $2,086,000 after buying an additional 700 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Down 2.2%

Shares of NYSE CRL traded down $2.97 during trading hours on Friday, reaching $134.73. The stock had a trading volume of 149,150 shares, compared to its average volume of 990,757. The firm has a market cap of $6.62 billion, a price-to-earnings ratio of 898.54, a P/E/G ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The business's fifty day moving average price is $129.55 and its two-hundred day moving average price is $161.31.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same period in the previous year, the company posted $2.27 earnings per share. The business's revenue was down 2.7% on a year-over-year basis. Analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on CRL shares. Barclays boosted their price target on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a report on Thursday, May 8th. Morgan Stanley reduced their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Mizuho cut their price objective on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and an average price target of $171.85.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).